Royal Bank of Canada started coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report released on Thursday, Marketbeat Ratings reports. The firm issued an outperform rating and a $126.00 price target on the stock. AXSM has been the topic of a number of other reports. Cantor Fitzgerald reiterated an overweight rating […]
HC Wainwright restated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report released on Tuesday, Marketbeat Ratings reports. HC Wainwright currently has a $180.00 price target on the stock. A number of other equities research analysts have also recently commented on AXSM. Cantor Fitzgerald restated an overweight rating […]
Cantor Fitzgerald restated their overweight rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report issued on Wednesday morning, Benzinga reports. They currently have a $108.00 price objective on the stock. Several other research analysts have also weighed in on AXSM. HC Wainwright restated a buy rating and set a $180.00 target […]
Citigroup started coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report released on Wednesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $125.00 target price on the stock. AXSM has been the topic of several other reports. HC Wainwright restated a buy rating and set a $180.00 […]
Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) have received a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 […]